Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–13 of 13 trials
Active filters
Clinical trials found
Published and searchable clinical trials
Searching for clinical trials...
Recruiting
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
NCT06176690
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, +17 more
- Locations
-
- Houston Methodist Hospital Houston, Texas, United States
- Texas Children's Hospital Houston, Texas, United States
NCT07013565
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- New York Medical College Valhalla, New York, United States
Recruiting
A Registry for People With T-cell Lymphoma
NCT05978141
- Conditions
- Adult T-Cell Leukemia/Lymphoma, Aggressive NK-cell Leukemia, Anaplastic Large Cell Lymphoma, ALK-Positive, +54 more
- Locations
-
- City of Hope Cancer Center (Data collection only) Duarte, California, United States
- UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only) San Diego, California, United States
- University of California San Francisco (Data collection only) San Francisco, California, United States
- Stanford University Medical Center (Data collection only) Stanford, California, United States
Recruiting
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
NCT04925609
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Granuloma, Granuloma, Plasma Cell, +15 more
- Locations
-
- Institut Gustave Roussy Paris, France
- Princess Máxima Center for Pediatric Oncology Utrecht, Netherlands
Not Yet Recruiting
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
NCT07729397
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Diffuse Large B-Cell Lymphoma (DLBCL), +17 more
- Locations
-
- Houston Methodist Hospital Houston, Texas, United States
NCT03505554
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
- Locations
-
- Irccs San Gerardo Dei Tintori Monza, Italy/MB, Italy
- UOC Ematologia, Ospedale S. Eugenio Roma, Italy
Completed
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451
- Conditions
- ALK-Positive Anaplastic Large Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, +36 more
- Locations
-
- British Columbia Cancer Agency the Vancouver Centre Vancouver, British Columbia, Canada
- Peking University Third Hospital Beijing, Beijing Municipality, China
- Beijing Hospital Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital Beijing, Beijing Municipality, China
NCT01979536
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, +12 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
- Arkansas Children's Hospital Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center Downey, California, United States
NCT02561273
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Enteropathy-Associated T-Cell Lymphoma, +21 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- Stanford Cancer Institute Palo Alto, California, United States
- University of Colorado Cancer Center, Anschutz Cancer Pavilion Aurora, Colorado, United States
- Emory University/Winship Cancer Institute Atlanta, Georgia, United States
NCT03603847
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- CHU Amiens - Hôpital Sud Amiens, France
- CHU d'Estaing Clermont-Ferrand, France
- APHP - Hopital Henri Mondor Créteil, France
- CHU Grenoble Grenoble, France
NCT02419287
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- ASST-Monza Monza, Italy/MB, Italy
Active, Not Recruiting
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
NCT02978625
- Conditions
- Adenocarcinoma, Adenocarcinoma, Papillary, Anaplastic Large Cell Lymphoma, ALK-Positive, +86 more
- Locations
-
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
- Keck Medical Center of USC Pasadena Pasadena, California, United States
Active, Not Recruiting
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
NCT03113500
- Conditions
- Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, +26 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- Hackensack University Medical Center Hackensack, New Jersey, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- M D Anderson Cancer Center Houston, Texas, United States